Navigation Links
'VAP with a Pap' Campaign Targets Women and Heart Disease

BIRMINGHAM, Ala., Feb. 4 /PRNewswire/ -- More than five times as many women are diagnosed with heart disease each year than with breast cancer. American Heart Month in February aims to spread awareness of women and heart disease, and one Alabama company has found the quickest way to a woman's heart might be through her gynecologist.


A growing number of gynecologists around the nation are turning to Atherotech Inc., developers of the VAP Cholesterol Test, for its advanced lipid profile. The blood test gives physicians a better understanding of a woman's risk of heart attack and stroke. Combining the VAP Test with a Pap test — which detects early changes of the cervix before they become cancer — makes an easy-to-remember combination for two of the most important preventive health tests for women.

"It seems a bit unusual at first, but if there's one check up most women don't skip, it's their annual OB/GYN visit," said Michael Cobble, M.D., Chief Medical Officer of Atherotech Inc. "Women may naturally feel more comfortable discussing health issues with an OB/GYN, and this opens the door to other conversations such as cholesterol levels and heart disease risk."

Monitoring cholesterol levels is key to early intervention and prevention of heart disease. Studies have shown that most adult women see their gynecologists once a year for an annual women's wellness visit, but often pass on a primary care physician visit, potentially missing out on other preventive health services such as cholesterol testing and immunizations.

"A woman's annual gynecologic examination is often the only routine preventive care they receive," said Steven Foley, M.D. "I first realized the VAP with a Pap was a perfect fit for my practice several years ago and have been using it ever since."

The Colorado Springs, Colo., gynecologist now uses the VAP Test to more accurately assess heart disease risk and to evaluate patients for polycystic ovarian syndrome (PCOS), diabetes and infertility. Foley explained that the VAP Test plays a role in the diagnosis of PCOS because, as an expanded cholesterol test, it measures a range of cholesterol subclasses not measured by the routine cholesterol test.

The VAP Test reports 22 separate components of blood compared to just four in the standard cholesterol test (LDL, HDL, total cholesterol and triglycerides) at no additional cost. This advanced lipid panel does not require fasting and includes a measurement of the patient's Lp(a), an important risk factor much discussed in recent publications, as part of its standard panel.

The American Heart Association recommends cholesterol screening starting at the age of 20. Foley routinely uses the VAP Test on patients over the age of 45 who come in for an annual exam and who have not had a cholesterol test within the past 12 months. He also initially tests all patients one time between the ages of 30-45.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit

About Atherotech Inc.

Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit


(According to American Heart Association, American Cancer Society, and the National Institutes of Health)

  • About 64 percent of women who die of cardiovascular disease have no prior symptoms.
  • Women are less likely than men to have their cholesterol lowered through treatment and are less likely to be treated for heart disease as aggressively as men.
  • Heart disease is the No. 1 cause of death among women age 40 and above, followed by stroke, lung cancer, lung diseases and breast cancer.
  • Since 1963, Congress has required the president to proclaim February "American Heart Month."
  • The goal of American Heart Month is to raise funds for research and education and pass along information about heart disease and stroke.

SOURCE Atherotech Inc.



SOURCE Atherotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Executive Shares Why Ohio is the Perfect Location for Bioscience Business in National Ad Campaign
2. Biomedical Research Organization Launches Groundbreaking National TV Campaign
3. Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings Announces National Print Advertising Campaign for Cobroxin, a Treatment for Moderate to Severe (Stage 2) Pain
4. avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin(R) Psoriasis Relief DRTV Campaign
5. avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
6. Campaign to Increase the Awareness and Understanding of Lou Gehrigs Disease Reaches 22 U.S. States
7. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Photos: Project Runways Tim Gunn Launches Addressing Psoriasis(TM) Campaign to Advocate That Patients Shouldnt Let Psoriasis Impact Personal Style
9. BioSpace and the Massachusetts Biotechnology Council Inc. Launch 2009 Genetown™ Hotbed Campaign
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... were featured on AngelList early in their initial angel funding process. Now, they ... for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... Oct. 29, 2015 Today, LifeBEAM ... partnership with 2XU, a global leader in technical ... smart hat with advanced bio-sensing technology. The hat ... to monitor key biometrics to improve overall training ... the two companies will bring together the most advanced ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):